JP2013177430A5 - - Google Patents

Download PDF

Info

Publication number
JP2013177430A5
JP2013177430A5 JP2013111446A JP2013111446A JP2013177430A5 JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5 JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5
Authority
JP
Japan
Prior art keywords
cells
cancer
killed
dendritic
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013111446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013177430A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013177430A publication Critical patent/JP2013177430A/ja
Publication of JP2013177430A5 publication Critical patent/JP2013177430A5/ja
Pending legal-status Critical Current

Links

JP2013111446A 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 Pending JP2013177430A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518581A Division JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015207617A Division JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Publications (2)

Publication Number Publication Date
JP2013177430A JP2013177430A (ja) 2013-09-09
JP2013177430A5 true JP2013177430A5 (enExample) 2014-06-26

Family

ID=38895372

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2013111446A Pending JP2013177430A (ja) 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Country Status (8)

Country Link
US (1) US20080031900A1 (enExample)
EP (2) EP2630968A1 (enExample)
JP (3) JP2009542714A (enExample)
KR (1) KR20090033375A (enExample)
CN (1) CN101511384A (enExample)
AU (1) AU2007269245B2 (enExample)
CA (1) CA2691346A1 (enExample)
WO (1) WO2008005859A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728772A1 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2547360A4 (en) * 2010-03-15 2013-11-20 Univ Pennsylvania SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS
KR20140054140A (ko) * 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
CN105999249A (zh) * 2011-10-20 2016-10-12 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
CA2896994A1 (en) * 2012-12-28 2014-07-03 Amphera B.V. Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
EP2787005A1 (en) * 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
US20180066229A1 (en) * 2015-03-17 2018-03-08 Shinshu University Method for preparing dendritic cells via non-adhesive culture using ifn
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
US12329807B2 (en) * 2018-01-18 2025-06-17 Meganano Biotech, Inc. Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
CA3132072A1 (en) * 2019-03-01 2020-09-10 Gritstone Bio, Inc. Selection of t cell receptors
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023013211A (ja) * 2021-07-15 2023-01-26 大日本印刷株式会社 細胞医薬品の提供方法、細胞医薬品用ラベルの作成方法、情報処理方法、プログラム、細胞医薬品、細胞医薬品容器および細胞医薬品提供システム
US12433915B2 (en) 2022-11-23 2025-10-07 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
ATE388237T1 (de) 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
ATE328607T1 (de) * 1998-01-16 2006-06-15 Biomira Usa Inc Von membran-proteoliposomen patient-spezifischen bösartigen weissen blutzellen impstoff
CA2321093A1 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
ATE552011T1 (de) * 2003-10-15 2012-04-15 Ist Superiore Sanita Kolorektal-karzinom-antigen
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Similar Documents

Publication Publication Date Title
JP2013177430A5 (enExample)
JP2010514455A5 (enExample)
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
Hope et al. Striking a balance—cellular and molecular drivers of memory T cell development and responses to chronic stimulation
JP2014514927A5 (enExample)
JP2015131795A5 (enExample)
Andersen The specific targeting of immune regulation: T-cell responses against Indoleamine 2, 3-dioxygenase
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
MX350795B (es) Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
BR112019001656A2 (pt) composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
BR112020015512A2 (pt) método de produção de células exterminadoras naturais e composição para tratamento de câncer
RU2012127685A (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
Singh et al. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
Liu et al. Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design
JP2012021028A5 (enExample)
JP2018522880A5 (enExample)
JP2014533938A5 (enExample)
Shui et al. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells
JP6042065B2 (ja) 能動免疫療法のためのＴｈ１ワクチン接種プライミング
JP2014516538A5 (enExample)
MX2013013243A (es) Medios y metodos para activar la inmunoterapia celular del cancer utilizando celulas cancerosas destruidas mediante presion hidrostatica y celulas dendriticas.
Bagirova et al. Overview of dendritic cell‐based vaccine development for leishmaniasis
AU2018251949A1 (en) Compounds, composition and uses thereof for treating cancer
JP2019508056A5 (enExample)